Long-Term Humoral and Cellular Immune Response to Hepatitis B Vaccine in High-Risk Children 18–20 Years After Neonatal Immunization

Chinchai, Teeraporn; Chirathaworn, Chintana; Praianantathavorn, Kesmanee; Theamboonlers, Apiradee; Hutagalung, Yanee; Hans, P L Bock; Thantiworasit, Pattarawat; Poovorawan, Yong

doi:10.1089/vim.2008.0087

Cited by 33 publications

(31 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The long-term persistence data are in agreement with previous studies conducted in Thailand 8 , 9 , 11 - 14 and elsewhere 15 , 16 in children less than 5 y of age. Vaccination-induced HBV immunity persists from infancy for at least 20 y following vaccination 8 , 9 , 11 …”

Section: Discussionsupporting

confidence: 92%

Long-term anti-HBs antibody persistence following infant vaccination against hepatitis B and evaluation of anamnestic response

Poovorawan

Chongsrisawat

Theamboonlers

et al. 2013

Human Vaccines & Immunotherapeutics

Self Cite

View full text Add to dashboard Cite

Hepatitis B vaccine has been available worldwide since the mid-1980s. This vaccine was evaluated in a clinical trial in Thailand, conducted on subjects born to hepatitis B surface antigen positive and hepatitis B e-antigen positive mothers and vaccinated according to a 4-dose schedule at 0, 1, 2 and 12 mo of age and a single dose of hepatitis B immunoglobulin concomitantly at birth. All enrolled subjects seroconverted and were followed for 20 y to assess the persistence of antibody to the hepatitis B surface antigen (anti-HBs) (NCT00240539). At year 20, 64% of subjects had anti-HBs antibody concentrations ≥ 10 milli-international units per milli liter (mIU/ml) and 92% of subjects had detectable levels (≥ 3.3 mIU/ml) of anti-HBs antibodies. At year 20, subjects with anti-HBs antibody titer < 100 mIU/ml were offered an additional dose of hepatitis B virus (HBV) vaccine to assess immune memory (NCT00657657). Anamnestic response to the challenge dose was observed in 96.6% of subjects with an 82-fold (13.2 to 1082.4 mIU/ml) increase in anti-HBs antibody geometric mean concentrations. This study confirms the long-term immunogenicity of the 4-dose regimen of the HBV vaccine eliciting long-term persistence of antibodies and immune memory against hepatitis B for up to at least 20 y after vaccination.

show abstract

Section: Discussionsupporting

confidence: 92%

Long-term anti-HBs antibody persistence following infant vaccination against hepatitis B and evaluation of anamnestic response

Poovorawan

Chongsrisawat

Theamboonlers

et al. 2013

Human Vaccines & Immunotherapeutics

Self Cite

View full text Add to dashboard Cite

show abstract

“…In fact, B and T memory cells use different survival factors and as such, B-cell and T-cell immunity decline at different rates, and individual cell lifespans may differ. This disconnect between memory T cells and neutralizing Ab titers has been seen with other viral pathogens such as vaccinia and hepatitis B (6,11). To better discern correlations between humoral and cellular markers of immunity to rubella at the time of initial antigenic challenge, a subsequent study should be conducted shortly after initial rubella vaccination, when primary T- and B-cell responses are at their peak.…”

Section: Discussionmentioning

confidence: 70%

Correlation Between Rubella Antibody Levels and Cytokine Measures of Cell-Mediated Immunity

et al. 2009

View full text Add to dashboard Cite

Despite a safe and effective vaccine, endemic rubella remains a problem in developing countries. Isolated cases and outbreaks can occur in areas with high vaccine coverage. Individuals, especially pregnant women who remain unimmunized or do not seroconvert, are susceptible to infection and their infants are at risk for congenital rubella syndrome (CRS). Both humoral and cellular immune responses contribute to immune protection. Classically, immunity to rubella has been assessed through the detection of rubella-specific antibody titers. In this study we examined correlates of both humoral and cellular immunity in a large population of immunized young adults in Olmsted County, MN. We were unable to find any significant correlation between cytokine production after in-vitro rubella stimulation and serum antibody titers.

show abstract

“…7 These divergent values all indicate that the humoral and cellular response to HBV vaccine was different in each participant, although they were subject to the same vaccination schedule. 26 In the "unvaccinated" students group, 4.8% were anti-HBs positive, which could be explained by an unregistered vaccination or may be due to past or present HBV infection. These "unvaccinated" students had levels of anti-HBs at 501-1000 mIU/mL (Table 3), and they were negative to anti-HBc (IgG/IgM) or HBsAg by CMIA, whereas the rest of the group (95.2%) had no antibodies.…”

Section: Discussionmentioning

confidence: 92%

Hepatitis B surface antibodies in medical students from a public university in Puebla, Mexico

Cárdenas-Perea

Gómez-Conde

Santos‐López

et al. 2016

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

Although preventable with vaccination, Hepatitis B virus (HBV) infection is a major health concern, with »400 million people at risk of developing the chronic form of the disease worldwide. The anti-HBV vaccine consists of a recombinant HBV surface antigen (HBsAg), which induces specific anti-HBs antibodies and confers 95% protection for >20 y. The aim of the present study was to analyze the response to HBV vaccination by measuring anti-HBs antibodies in serum samples from medical students of a public university in Puebla, Mexico. HBV infection markers HBsAg and anti-HBs, were also determined. A total of 201 students were included and vaccination coverage was found at 54%. Overall seropositivity for HBsAg, anti-HBc and anti-HBs determined by ELISA was 0.5%, 1.0% and 47%, respectively. Protective levels of anti-HBs >10 mIU/mL were found in 93.2% of subjects vaccinated with 2 or 3 doses and in 40% of those vaccinated with a single dose; while only 4.8% of unvaccinated subjects were anti-HBs positive. The response to the HBV vaccine was different in each participant, despite similar vaccination scheme. A history of blood transfusion/organ transplant or more than 2 sexual partners was significantly associated with anti-HBc positivity, OR D 399 (p D 0.010) and OR D 19.9 (p D 0.044), respectively. HBV immunization coverage was low in our sample compared with reports from countries with similar HBV prevalence, but anti-HBs in vaccinated individuals were in the expected range. It is important to promote HBV vaccination and awareness among medical students, due to their exposure risk.

show abstract

Long-Term Humoral and Cellular Immune Response to Hepatitis B Vaccine in High-Risk Children 18–20 Years After Neonatal Immunization

Cited by 33 publications

References 24 publications

Long-term anti-HBs antibody persistence following infant vaccination against hepatitis B and evaluation of anamnestic response

Long-term anti-HBs antibody persistence following infant vaccination against hepatitis B and evaluation of anamnestic response

Correlation Between Rubella Antibody Levels and Cytokine Measures of Cell-Mediated Immunity

Hepatitis B surface antibodies in medical students from a public university in Puebla, Mexico

Contact Info

Product

Resources

About